Why China's expanding pharma market is still a risky bet

| BY

clpstaff &clp articles

China's pharmaceutical market is expanding rapidly, but recent policy developments mean multinationals need to rethink their strategy

Statistics from CITI predict China will have a $200 billion pharmaceutical market by 2020, making it the second largest in the world. “This begs the question can multinationals afford not to expand considering how fast the market is growing compared to the global market?” said Christoph Hezel, a lawyer specialising in healthcare at Taylor Wessing in Beijing.

This expected growth should translate into exciting growth opportunities for healthcare multinationals. But policy developments and government pressure to increase healthcare access while controlling costs are taking a toll.

This premium content is reserved for
China Law & Practice Subscribers.

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]